SGEM#511: I’d Like To Treat, DKA with the SQuID Protocol

Trials extracted from the podcast by Dr. Ken Milne

• 2025Safety and Effectiveness of Subcutaneous Insulin for Management of Mild to Moderate Diabetic Ketoacidosis in Nonpregnant IndividualsEndocrine & DiabetesIn adults with mild to moderate diabetic ketoacidosis, subcutaneous insulin closed the anion gap slower than intravenous insulin, with less hypoglycemia
• 2023SQuIDEndocrine & DiabetesIn 177 adults with mild-to-moderate DKA, a subcutaneous fast-acting insulin protocol shortened ED length of stay compared with intravenous insulin infusion.
• 2025SQuID IIEndocrine & DiabetesIn 84 adults with mild-to-moderate diabetic ketoacidosis, subcutaneous insulin shortened time on treatment without more hypoglycaemia than intravenous insulin.
• 2022Hospital-Wide Implementation of a Subcutaneous Insulin Protocol for Diabetic KetoacidosisEndocrine & DiabetesIn 7989 hospitalizations for diabetic ketoacidosis, a subcutaneous insulin protocol cut ICU admission and 30-day readmission versus standard intravenous insulin care.
• 2026CRABI-DKAEndocrine & DiabetesIn adults with mild to moderate ketoacidosis, subcutaneous basal-plus-rapid insulin resolved DKA within 12 hours as often as intravenous insulin infusion.